| Popis: |
Supplemental Figure 1. Structures of PARP1 inhibitors used; Supplemental Figure 2. Clonogenicity of HCT116 cells with wild type p53 and p53 KO in response to imatinib (A, 5 - 50 μM, continuous incubation) or CNDAC (B, 0.05 - 0.4 μM, 24-hour exposure); Supplemental Figure 3. HR deficient cells are sensitized to PARP inhibitors; Supplemental Figure 4. Clonogenicity of Xrcc3, Rad51D and BRCA2 hamster lines after temozolomide or CNDAC; Supplemental Figure 5. Clonogenicity of Xrcc3, Rad51D, and Brca2 CHO lines in response to bendamustine or 4-HC; Supplemental Figure 6. Clonogenicity of BRCA2, XRCC3, RAD51D, and XPF CHO lines after cisplatin or oxaliplatin; Supplemental Table 1. IC50 values of clonogenic assays in RAD51D and BRCA2 hamster lines in response to paclitaxel or docetaxel. |
